Targeting the distal small intestine, specifically the terminal ileum, remains one of the greatest challenges in oral drug delivery.
Innovation in oral formulation technologies has opened new avenues for the lifecycle management and patent protection of biologics. Technologies such as SNAC, LBFs,…
The success and adoption of oral GLP-1 RAs mark a shift in biologic drug delivery. Technologies such as permeation enhancers, LBFs, and enteric protection have made…
Healthcare systems are facing increasing pressure as record demand, an aging population, the burden of chronic disease, and economic inflation challenge clinics,…
Meeting consumers’ needs is the first priority for any successful business. For over-the-counter (OTC) medications and supplements, oral dosage forms have long been…
Discover how next-generation capsule technologies, including Capsugel(R) Enprotect(R) capsules, are advancing targeted oral drug delivery, improving bioavailability,…
The capsule market is shifting due to the growing importance of ethics and sustainability in driving consumer behavior. The ethical spending market has shown…
Maximizing Productivity in Vegan and Vegetarian Capsules Filling
Delivering orally bioavailable biologic modalities requires expertise in multiple fields. Lonza Capsugel scientists and technologists are dedicated to working with…
Biological therapies have transformed the treatment of chronic and complex diseases, yet their impact is often limited by the need for parenteral administration.…
Sustainability is at the core of our business strategy and operating philosophy.
In our latest podcast, Lonza Capsugel’s Frank Romanski explores how patient preference is reshaping development strategies.
For years, oral delivery of biologics has been viewed as impractical. But what if the issue is not the route, but the approach?
Understanding patient attitudes and preferences has become an essential part of modern therapeutic decision making. The effectiveness of therapies doesn’t solely…
Contact Us